What is Dexmethylphenidate?
Dexmethylphenidate is the active d-threo enantiomer of methylphenidate and is marketed as a prescription medicine under the brand name Focalin. Whereas conventional methylphenidate products generally contain a racemic mixture of d- and l-threo forms, dexmethylphenidate contains the d-threo form alone. This is a difference in stereochemistry, not a separate stimulant family.
The distinction is pharmacologically relevant because most of the central stimulant activity of methylphenidate is associated with its d-threo enantiomer. The relationship between the two medicines is discussed in the literature on methylphenidate (Ritalin) and its isomers.
Chemistry and stereochemistry
Dexmethylphenidate has the same molecular connectivity as methylphenidate. The two substances differ in the three-dimensional arrangement of atoms around their chiral centres. Methylphenidate is commonly supplied as a racemic threo mixture, while dexmethylphenidate isolates the d-threo form. That makes it possible to deliver the principal active enantiomer without the corresponding l-threo component.
Pharmacology and clinical use
Dexmethylphenidate is a central nervous system stimulant prescribed for attention-deficit/hyperactivity disorder (ADHD). It inhibits the dopamine transporter (DAT) and norepinephrine transporter (NET), reducing the reuptake of these neurotransmitters and increasing their availability outside nerve cells. The precise way in which this action produces clinical improvement in ADHD is not fully established.
In clinical treatment, the intended changes are better sustained attention and reduced hyperactivity and impulsivity. These are therapeutic outcomes observed in patients, not a description of a recreational experience. The current US prescribing information is available through the DailyMed dexmethylphenidate label.
Effects and adverse reactions
Clinical use, trials and post-marketing surveillance provide the main evidence for dexmethylphenidate’s effects and adverse reactions. Responses vary with the patient, formulation and clinical context.
| Intended clinical effects | Reported adverse effects |
|---|---|
|
|
In the paediatric clinical-trial data summarized in the prescribing information, abdominal pain, fever, reduced appetite and nausea were among the more common adverse reactions. The label also records less frequent but more serious reactions, including psychiatric symptoms and cardiovascular complications. A listed adverse event does not mean that it will occur in every patient, and spontaneous reports do not always establish a direct cause.
Medical context
Dexmethylphenidate is a regulated prescription medicine, not an unapproved research chemical. Its clinical evidence base is substantially larger than that of most methylphenidate analogues sold online. It nevertheless carries recognised risks when used outside medical supervision, including misuse and abuse, and the prescribing information includes warnings about these risks. Its therapeutic use should be distinguished from non-medical exposure to other phenidates.

Reviews
There are no reviews yet.